Biosimilars

Celebrate the people, companies, and innovations had the biggest impact on pharma in the last year.

One decade behind the EU, biosimilars are arriving in the US. What can we expect? Jeff Baldetti from Cardinal Health has a few ideas.

To keep biosimilars costs as low as possible, take a good look at your purification and characterization processes.

A new report has exposed a Humira US price hike that dwarfs the rises in the price of other drugs.

The FDA has approved just three biosimilars in 2021 – but the approvals could shake up the field as discussions around interchangeability intensify.

Sandoz’s Pierre Bourdage talks to us about biosimilars and how uptake can be boosted.

Kiran Mazumdar-Shaw shares the experiences that have helped shape her career, and the lessons learned along the way.

The FDA has approved its first biosimilar of 2020: Pfizer’s Nyvepria (pegfilgrastim-apgf).

Cures for all presents a real focus for the next decade – but companies must be rewarded for their work.

We must never forget unmet needs when developing new medicines.